

Fibro-adipose Vascular Anomaly

Jennifer Laborada^{1,2} and Deborah E. Schiff^{1,3*}


¹Rady Children's Hospital, San Diego, CA

²UC Riverside School of Medicine, Riverside, CA

³UC San Diego School of Medicine, La Jolla, CA

***Corresponding author:** Deborah E. Schiff, Rady Children's Hospital, San Diego, CA; UC San Diego School of Medicine, La Jolla, CA. E-mail: dschiff@rchsd.org

Received: July 30, 2022; **Accepted:** August 08, 2022; **Published:** August 21, 2022



Clinical Image

A 9-year-old boy presented with a 10-month history of a swollen, painful right thigh and inability to weight-bear (A). MRI/MRA demonstrated a large low-flow heterogeneous fat-containing soft tissue mass that infiltrated the adductor muscle (B). A non-diagnostic needle biopsy revealed myositis with small vessel lymphocytic vasculitis, vascular changes, and edema. A diagnosis of fibro-adipose vascular anomaly (FAVA) was rendered by the multidisciplinary Vascular Anomalies Team. He was treated with oral mTOR inhibitor sirolimus, and within 3 months, he could fully weight-bear with decreased pain and swelling (C). Repeat MRI after 1 year of sirolimus showed decreased size and enhancement of the right thigh mass (D).

FAVA is a rare vascular anomaly characterized by fatty infiltration of affected muscles. Most cases are caused by somatic PIK3CA mutations. Severe pain and muscle contractures are common features. Treatment includes systemic therapy with inhibitors of the PI3K/AKT/mTOR pathway, cryoablation, surgical resection, and physical therapy.